The Transparency Commission of the French National Health Authority has granted market access for Cell Therapeutics' (CTI) aggressive non-hodgkin lymphoma treatment, Pixuvri (pixantrone) in France. Pixuvri is indicated as monotherapy for ...
The Italian Medicines Agency (AIFA) has granted market access to Cell Therapeutics for the medicinal product, Pixuvri (pixantrone), a novel aza-anthracenedione with structural and physiochemical properties Pixuvri has been approved as a ...
Cell Therapeutics (CTI) has announced the European launch of Pixuvri for the treatment of adult patients with multiply relapsed or refractory aggressive non-hodgkin B-cell lymphoma. The company initiated the launch with entry into Sweden, ...
Tags: Cell Therapeutics, Pixuvri, NHL, B-cell lymphoma
The European Commission (EC) has awarded a conditional marketing authorization approval for Cell Therapeutics' Pixuvri (pixantrone) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive ...
Tags: marketing authorization, pharmaceutical product, Pixuvri